MX2021010441A - Receptores antigenicos quimericos y agentes de union dirigidos a dll3. - Google Patents
Receptores antigenicos quimericos y agentes de union dirigidos a dll3.Info
- Publication number
- MX2021010441A MX2021010441A MX2021010441A MX2021010441A MX2021010441A MX 2021010441 A MX2021010441 A MX 2021010441A MX 2021010441 A MX2021010441 A MX 2021010441A MX 2021010441 A MX2021010441 A MX 2021010441A MX 2021010441 A MX2021010441 A MX 2021010441A
- Authority
- MX
- Mexico
- Prior art keywords
- dll3
- chimeric antigen
- binding agents
- antigen receptors
- targeting chimeric
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 6
- 239000011230 binding agent Substances 0.000 title abstract 2
- 101150009796 Dll3 gene Proteins 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 102100036466 Delta-like protein 3 Human genes 0.000 abstract 6
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 abstract 6
- 229940127276 delta-like ligand 3 Drugs 0.000 abstract 6
- 210000002865 immune cell Anatomy 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464404—Epidermal growth factor receptors [EGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/55—Lung
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
En la presente descripción se proporcionan agentes de unión a DLL3 y receptores antigénicos quiméricos (CAR) que comprenden una molécula de unión a DLL3 que se une específicamente a DLL3; y células inmunitarias que comprenden estos CAR específicos para DLL3, por ejemplo, células CAR-T. También se proporcionan métodos para producir y usar CAR específicos para DLL3 y células inmunitarias que comprenden CAR específicos para DLL3.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962812585P | 2019-03-01 | 2019-03-01 | |
US202062969976P | 2020-02-04 | 2020-02-04 | |
PCT/US2020/020042 WO2020180591A1 (en) | 2019-03-01 | 2020-02-27 | Dll3 targeting chimeric antigen receptors and binding agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021010441A true MX2021010441A (es) | 2021-09-21 |
Family
ID=70057267
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021010441A MX2021010441A (es) | 2019-03-01 | 2020-02-27 | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. |
Country Status (14)
Country | Link |
---|---|
US (2) | US11673953B2 (es) |
EP (1) | EP3930744A1 (es) |
JP (1) | JP2022523781A (es) |
KR (1) | KR20210138574A (es) |
CN (1) | CN113543799A (es) |
AU (1) | AU2020231308A1 (es) |
CA (1) | CA3131908A1 (es) |
CO (1) | CO2021011326A2 (es) |
IL (1) | IL285943A (es) |
MX (1) | MX2021010441A (es) |
PE (1) | PE20220495A1 (es) |
SG (1) | SG11202108011UA (es) |
TW (1) | TW202045547A (es) |
WO (1) | WO2020180591A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116194488A (zh) * | 2020-07-21 | 2023-05-30 | 艾洛基治疗公司 | 具有增强的信号传导和活性的嵌合抗原受体和其用途 |
WO2022076788A1 (en) * | 2020-10-09 | 2022-04-14 | Memorial Sloan Kettering Cancer Center | Compositions targeting ndc80/mhc complexes and uses thereof |
AU2021409801A1 (en) | 2020-12-21 | 2023-06-22 | Allogene Therapeutics, Inc. | Protease-activating cd45-gate car |
AU2022212130A1 (en) | 2021-01-29 | 2023-07-06 | Allogene Therapeutics, Inc. | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS |
EP4335456A1 (en) * | 2021-05-08 | 2024-03-13 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | Binding molecule against dll3 and use thereof |
WO2023034555A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
CN114181311B (zh) * | 2021-12-20 | 2023-06-20 | 华东师范大学 | 一种全人源抗DLL3 scFv及其在CART细胞治疗中的应用 |
US20230346934A1 (en) | 2022-03-29 | 2023-11-02 | Allogene Therapeutics, Inc. | Chimeric switch receptors for the conversion of immunesuppressive signals to costimulatory signals |
US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
WO2024044779A2 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US6319494B1 (en) | 1990-12-14 | 2001-11-20 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
EP0617706B1 (en) | 1991-11-25 | 2001-10-17 | Enzon, Inc. | Multivalent antigen-binding proteins |
IL104570A0 (en) | 1992-03-18 | 1993-05-13 | Yeda Res & Dev | Chimeric genes and cells transformed therewith |
US5830462A (en) | 1993-02-12 | 1998-11-03 | President & Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5869337A (en) | 1993-02-12 | 1999-02-09 | President And Fellows Of Harvard College | Regulated transcription of targeted genes and other biological events |
US5834266A (en) | 1993-02-12 | 1998-11-10 | President & Fellows Of Harvard College | Regulated apoptosis |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US20030036654A1 (en) | 1994-08-18 | 2003-02-20 | Holt Dennis A. | Synthetic multimerizing agents |
US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
PT1034298E (pt) | 1997-12-05 | 2012-02-03 | Scripps Research Inst | Humanização de anticorpo murino |
US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
RU2386638C2 (ru) | 2004-03-31 | 2010-04-20 | Дженентек, Инк. | Гуманизированные анти-тфр-бета-антитела |
US20100196336A1 (en) | 2006-05-23 | 2010-08-05 | Dongsu Park | Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods |
WO2011146862A1 (en) | 2010-05-21 | 2011-11-24 | Bellicum Pharmaceuticals, Inc. | Methods for inducing selective apoptosis |
PT3214091T (pt) | 2010-12-09 | 2019-01-11 | Univ Pennsylvania | Utilização de células t modificadas por recetor de antigénio quimérico para tratar o cancro |
AU2012209103B2 (en) | 2011-01-26 | 2015-12-03 | Takeda Pharmaceutical Company Limited | Methods and compositions for the synthesis of multimerizing agents |
BR112013024395B1 (pt) | 2011-03-23 | 2021-10-26 | Fred Hutchinson Cancer Research Center | Composições adotivas de imunoterapia celular e método para fabricação da dita composição |
BR112014020826A8 (pt) | 2012-02-24 | 2017-09-19 | Stem Centrx Inc | Anticorpo que se liga especificamente a um epítopo, ácido nucleico, vetor ou célula hospedeira, conjugado de fármaco anticorpo, composição farmacêutica compreendendo o referido anticorpo, uso do mesmo, kit e método de preparação do conjugado |
GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
CN110423282B (zh) | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | 嵌合抗原受体及其使用方法 |
SG11201506974XA (en) | 2013-03-14 | 2015-10-29 | Bellicum Pharmaceuticals Inc | Methods for controlling t cell proliferation |
CA2956667A1 (en) | 2013-07-29 | 2015-02-05 | Bluebird Bio, Inc. | Multipartite signaling proteins and uses thereof |
EP3087101A4 (en) | 2013-12-20 | 2017-12-06 | Novartis AG | Regulatable chimeric antigen receptor |
MX2016010171A (es) | 2014-02-04 | 2017-02-15 | Us Health | Metodos para producir celulas t autologas utiles para tratar desordenes de celulas b y otros tipos de cancer, y composiciones de las mismas. |
CN111849912B (zh) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | 用诱导型嵌合多肽活化t细胞的方法 |
AU2015218633A1 (en) | 2014-02-21 | 2016-09-01 | Abbvie Stemcentrx Llc | Anti-DLL3 antibodies and drug conjugates for use in melanoma |
ES2842212T3 (es) | 2015-01-26 | 2021-07-13 | Cellectis | Receptores de antígenos quiméricos monocatenarios específicos anti-CLL1 (scCAR) para inmunoterapia contra el cáncer |
MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
TW202346349A (zh) | 2015-07-31 | 2023-12-01 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
JP2018535655A (ja) * | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | Asgr阻害剤 |
UA123276C2 (uk) | 2016-04-01 | 2021-03-10 | Кайт Фарма, Інк. | Химерний рецептор та спосіб лікування пухлини або злоякісного новоутворення |
WO2018151841A1 (en) * | 2017-02-17 | 2018-08-23 | Sanofi | Multispecific binding molecules having specificity to dystroglycan and laminin-2 |
-
2020
- 2020-02-27 EP EP20715560.7A patent/EP3930744A1/en active Pending
- 2020-02-27 KR KR1020217025642A patent/KR20210138574A/ko unknown
- 2020-02-27 US US16/802,822 patent/US11673953B2/en active Active
- 2020-02-27 TW TW109106500A patent/TW202045547A/zh unknown
- 2020-02-27 SG SG11202108011UA patent/SG11202108011UA/en unknown
- 2020-02-27 JP JP2021550277A patent/JP2022523781A/ja active Pending
- 2020-02-27 WO PCT/US2020/020042 patent/WO2020180591A1/en active Application Filing
- 2020-02-27 PE PE2021001410A patent/PE20220495A1/es unknown
- 2020-02-27 MX MX2021010441A patent/MX2021010441A/es unknown
- 2020-02-27 AU AU2020231308A patent/AU2020231308A1/en active Pending
- 2020-02-27 CA CA3131908A patent/CA3131908A1/en active Pending
- 2020-02-27 CN CN202080018238.0A patent/CN113543799A/zh active Pending
-
2021
- 2021-08-27 CO CONC2021/0011326A patent/CO2021011326A2/es unknown
- 2021-08-29 IL IL285943A patent/IL285943A/en unknown
-
2023
- 2023-04-27 US US18/308,143 patent/US20230287120A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20210107979A1 (en) | 2021-04-15 |
WO2020180591A1 (en) | 2020-09-10 |
AU2020231308A1 (en) | 2021-08-19 |
TW202045547A (zh) | 2020-12-16 |
IL285943A (en) | 2021-10-31 |
CA3131908A1 (en) | 2020-09-10 |
CO2021011326A2 (es) | 2021-09-09 |
JP2022523781A (ja) | 2022-04-26 |
EP3930744A1 (en) | 2022-01-05 |
SG11202108011UA (en) | 2021-08-30 |
US20230287120A1 (en) | 2023-09-14 |
CN113543799A (zh) | 2021-10-22 |
US11673953B2 (en) | 2023-06-13 |
PE20220495A1 (es) | 2022-04-07 |
KR20210138574A (ko) | 2021-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021010441A (es) | Receptores antigenicos quimericos y agentes de union dirigidos a dll3. | |
PH12018500295A1 (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof | |
MX2020012927A (es) | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. | |
MX2020011744A (es) | Molecula de polipeptido con especificidad dual mejorada. | |
CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
PH12018500861A1 (en) | Antibody/t-cell receptor chimeric constructs and uses thereof | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MY192474A (en) | Chimeric antigen receptors targeting epidermal growth factor receptor variant iii | |
PH12019502637A1 (en) | Chimeric antigen receptors targeting flt3 | |
MX2017014056A (es) | Construcciones dirigidas a complejos de peptido e7 del subtipo 16 del virus de papiloma humano (hpv16-e7)/complejo principal de histocompatibilidad (mhc) y sus usos. | |
MX2021014178A (es) | Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam). | |
PH12021550361A1 (en) | Anti-avb8 antibodies and compositions and uses thereof | |
MX2018014863A (es) | Régimen de dosificación para proteína de fusión de tcr especifico de gp100 - scfv anti - cd3. | |
MX2020006818A (es) | Receptores quimericos multiespecificos que comprenden un dominio nkg2d, y metodos de uso de los mismos. | |
EA202192413A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ | |
PH12020552181A1 (en) | Constructs targeting prostate-specific membrane antigen (psma) and uses thereof | |
MX2022005884A (es) | Tecnologías de conjugación dirigida. | |
MX2022005815A (es) | Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. | |
MX2022016300A (es) | Anticuerpo anti-trop2. | |
MX2020010104A (es) | Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado. | |
WO2014016702A3 (en) | Humanized forms of monoclonal antibodies to human gnrh receptor | |
ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
PH12018500159A1 (en) | Constructs targeting psa peptide/mhc complexes and uses thereof | |
PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
MX2022005821A (es) | Terapia del carcinoma de celulas renales (rcc) usando linfocitos t modificados por ingenieria genetica dirigidos a cd70. |